CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Advances in integrating biomaterials with CAR-T cells for enhancing solid tumor therapy.
Advances in integrating biomaterials with CAR-T cells for enhancing solid tumor therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T(CAR-T)细胞免疫疗法已成为免疫肿瘤学中一种变革性的治疗模式。然而,CAR-T 疗法在实体瘤中的临床转化仍受到物理屏障、免疫抑制性肿瘤微环境(TME)以及治疗相关毒性的显著限制。生物材料领域的进展已展现出巨大潜力,可通过与CAR-T 细胞的协同整合来应对这些制约因素。本综述系统考察了CAR-T 细胞与多种生物材料平台联合应用的治疗策略,包括纳米颗粒、抗体功能化系统以及水凝胶。文章对生物材料在增强CAR-T 疗效中的多方面作用进行了批判性分析,具体包括促进T细胞活化与增殖、改善肿瘤靶向性以及重编程免疫抑制性TME。总体而言,本综述对CAR-T 与生物材料整合策略进行了全面分析,为推进实体瘤治疗提供了机制性与转化性见解。
Chimeric antigen receptor T (CAR-T) cell immunotherapy has emerged as a transformative modality in immuno-oncology.
However, the clinical translation of CAR-T therapy for solid tumors remains significantly limited by physical barriers, an immunosuppressive tumor microenvironment (TME), and treatment-related toxicities. Advances in biomaterials have demonstrated substantial potential to address these constraints through synergistic integration with CAR-T cells. This review systematically examines therapeutic applications of CAR-T cells combined with diverse biomaterial platforms, including nanoparticles, antibody-functionalized systems, and hydrogels.
Critical analysis is provided on the multifaceted roles of biomaterials in enhancing CAR-T efficacy, specifically by promoting T cell activation and proliferation, improving tumor targeting, and reprogramming the immunosuppressive TME. Collectively, this review delivers a comprehensive analysis of CAR-T-biomaterial integration strategies, offering mechanistic and translational insights to advance solid tumor therapies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。